Clinical Trials Browser

Phase 2/3 × Breast Neoplasms × 90 days × Clear all

NCT06926868 2026-05-29

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02364557 2026-05-19

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

Phase 2/3 Completed

129 enrolled 23 charts

Breast Neoplasms, Lymphatic Metastasis

NCT05889390 2026-05-15

NeoHTerMa

Phase 2/3 Active not recruiting

Hyperthermia, Breast Neoplasms

NCT06062810 2026-04-23

Drugs-SNPs

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT03315364 2026-04-01

OPTIMAL

Phase 2/3 Active not recruiting

Breast Neoplasms, Recurrence

NCT07294508 2026-03-20

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Phase 2/3 Recruiting

Breast Neoplasms

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT05766891 2026-03-16

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

Phase 2/3 Recruiting

Breast Neoplasms